Market Exclusivity "Give-Away" Gone In Bioterror Bill

Law360, New York (October 24, 2005, 12:00 AM EDT) -- The contentious “wildcard” provision for market exclusivity has been removed prior to a vote from an updated Biodefense bill on Capitol Hill, easing concerns of the generic drug industry while leaving intact other controversial language.

The so-called “BioShield II” bill has been approved by the Senate Committee on Health, Education, Labor and Pension (HELP). It was penned and introduced by Senator Richard Burr (R-NC) to prompt cooperation between the private and public sectors in drug development. Burr is chairman of the HELP Subcommittee on Bioterrorism and...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.